Back
 IJCM  Vol.11 No.9 , September 2020
Role of Pre-Operative of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in Prognosis of Hepatocellular Carcinoma
Abstract: Introduction: Hepatocellular carcinoma (HCC) has a poor prognosis and is ranked in the top 2 leading causes of death in Taiwan. The clinical features which affect survival rate should be noticed for alarming. We tried to study the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) for the predictor of prognosis of HCC. Patients and Methods: A total of 525 patients with HCC were undergone surgical or non-surgical treatment registered in Cancer Registry Center of our hospital. The clinical features included patient’s basic profiles, and neutrophil, lymphocyte and platelet count in the peripheral blood at the time of diagnosis. The ratio of neutrophil/lymphocyte and platelate/lymphocyte was measured and their survival rates were analyzed based on their ratio scales. Results: Three scales of NLR and PLR were ≤1.62, 1.63 - 2.57, ≥2.58 and ≤224, 225 - 253, ≥254 respectively. Either higher NLR ≥ 2.58 or higher PLR ≥ 254 was found mostly in the male and TMN stage III and IV with a significant difference (P < 0.01). The 5-year survival rates of NLR ≤ 1.62, 1.63 - 2.57, ≥2.58 were 33.9%, 33.7%, and 16.7% respectively (P < 0.001). The mean survival times were 34.1 ± 1.4, 29.3 ± 8.1, and 14.2 ± 2.1 months for the scales of PLR ≤ 224, 225 - 253, and ≥ 254 respectively. The 5-year survival rates were 25.5%, 36.4%, and 7.7% for the groups of the PLR ≤ 224, 225 - 253, and ≥254 respectively (p < 0.001). Conclusion: Neutrophil, lymphocyte and platelet are players in cancer growth and have a potential role as predictors of survival in our HCC patients. Therefore, we should pay more attention to the higher NLR or PLR which will result in a poorer prognosis in our patients.
Cite this paper: Ker, C. , Tong, H. , Yang, M. , Tseng, I. , Chang, D. , Chen, H. , Wang, B. , Ko, C. , Chao, C. and Chen, Y. (2020) Role of Pre-Operative of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in Prognosis of Hepatocellular Carcinoma. International Journal of Clinical Medicine, 11, 491-503. doi: 10.4236/ijcm.2020.119042.
References

[1]   Taiwan MoHaWo (2018) Top 10-Leading Causes of Death in Taiwan 2017.
https://wwwmohwgovtw

[2]   Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J. and Jemal, A. (2015) Global Cancer Statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87-108.
https://doi.org/10.3322/caac.21262

[3]   Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W., Comber, H., et al. (2013) Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012. European Journal of Cancer (Oxford, England: 1990), 49, 1374-1403.
https://doi.org/10.1016/j.ejca.2012.12.027

[4]   Itoh, S., Yugawa, K., Shimokawa, M., Yoshiya, S., Mano, Y., Takeishi, K., et al. (2019) Prognostic Significance of Inflammatory Biomarkers in Hepatocellular Carcinoma Following Hepatic Resection. BJS Open, 3, 500-508.
https://doi.org/10.1002/bjs5.50170

[5]   Hu, J., Wang, N., Yang, Y., Ma, L., Han, R., Zhang, W., et al. (2018) Diagnostic Value of Alpha-Fetoprotein Combined with Neutrophil-to-Lymphocyte Ratio for Hepatocellular Carcinoma. BMC Gastroenterology, 18, Article No. 186.
https://doi.org/10.1186/s12876-018-0908-6

[6]   Sprinzl, M.F., Kirstein, M.M., Koch, S., Seib, M.L., Weinmann-Menke, J., Lang, H., et al. (2019) Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. Liver Cancer, 8, 387-402.
https://doi.org/10.1159/000492628

[7]   He, C.B. and Lin, X.J. (2017) Inflammation Scores Predict the Survival of Patients with Hepatocellular Carcinoma Who Were Treated with Transarterial Chemoembolization and Recombinant Human Type-5 Adenovirus H101. PLoS ONE, 12, e0174769.
https://doi.org/10.1371/journal.pone.0174769

[8]   Wang, D., Bai, N., Hu, X., OuYang, X.W., Yao, L., Tao, Y., et al. (2019) Preoperative Inflammatory Markers of NLR and PLR as Indicators of Poor Prognosis in Resectable HCC. PeerJ, 7, e7132.
https://doi.org/10.7717/peerj.7132

[9]   Maucort-Boulch, D., de Martel, C., Franceschi, S. and Plummer, M. (2018) Fraction and Incidence of Liver Cancer Attributable to Hepatitis B and C Viruses Worldwide. International Journal of Cancer, 142, 2471-2477.
https://doi.org/10.1002/ijc.31280

[10]   Kanda, T., Goto, T., Hirotsu, Y., Moriyama, M. and Omata, M. (2019) Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review. International Journal of Molecular Sciences, 20, 1358.
https://doi.org/10.3390/ijms20061358

[11]   Coussens, L.M. and Werb, Z. (2002) Inflammation and Cancer. Nature, 420, 860-867.
https://doi.org/10.1038/nature01322

[12]   Mantovani, A., Savino, B., Locati, M., Zammataro, L., Allavena, P. and Bonecchi, R. (2010) The Chemokine System in Cancer Biology and Therapy. Cytokine & Growth Factor Reviews, 21, 27-39.
https://doi.org/10.1016/j.cytogfr.2009.11.007

[13]   Coffelt, S.B., Wellenstein, M.D. and de Visser, K.E. (2016) Neutrophils in Cancer: Neutral No More. Nature Reviews Cancer, 16, 431-446.
https://doi.org/10.1038/nrc.2016.52

[14]   Rollins, B.J. (2006) Inflammatory Chemokines in Cancer Growth and Progression. European Journal of Cancer (Oxford, England: 1990), 42, 760-767.
https://doi.org/10.1016/j.ejca.2006.01.002

[15]   Ludlam, C.A. (1980) The assessment of Platelet Function in Vivo by Measurement of Beta-Thromboglobulin, Platelet Factor 4 and Platelet Survival. Artery, 8, 470-474.

[16]   Dubernard, V., Arbeille, B.B., Lemesle, M.B. and Legrand, C. (1997) Evidence for an Alpha-Granular Pool of the Cytoskeletal Protein Alpha-Actinin in Human Platelets That Redistributes with the Adhesive Glycoprotein Thrombospondin-1 during the Exocytotic Process. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 2293-2305.
https://doi.org/10.1161/01.ATV.17.10.2293

[17]   Yang, H.J., Guo, Z., Yang, Y.T., Jiang, J.H., Qi, Y.P., Li, J.J., et al. (2016) Blood Neutrophil-Lymphocyte Ratio Predicts Survival after Hepatectomy for Hepatocellular Carcinoma: A Propensity Score-Based Analysis. World Journal of Gastroenterology, 22, 5088-5095.
https://doi.org/10.3748/wjg.v22.i21.5088

[18]   Rashtak, S., Ruan, X., Druliner, B.R., Liu, H., Therneau, T., Mouchli, M., et al. (2017) Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer. Clinical Colorectal Cancer, 16, 115-123e3.
https://doi.org/10.1016/j.clcc.2017.01.008

[19]   Graziano, V., Grassadonia, A., Iezzi, L., Vici, P., Pizzuti, L., Barba, M., et al. (2019) Combination of Peripheral Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymp-hocyte Ratio Is Predictive of Pathological Complete Response after Neoadjuvant Chemotherapy in Breast Cancer Patients. Breast (Edinburgh, Scotland), 44, 33-38.
https://doi.org/10.1016/j.breast.2018.12.014

[20]   Deng, M., Ma, X., Liang, X., Zhu, C. and Wang, M. (2017) Are Pretreatment Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Useful in Predicting the Outcomes of Patients with Small-Cell Lung Cancer? Oncotarget, 8, 37200-37207.
https://doi.org/10.18632/oncotarget.16553

[21]   Tas, M., Yavuz, A., Ak, M. and Ozcelik, B. (2019) Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Discriminating Precancerous Pathologies from Cervical Cancer. Journal of Oncology, 2019, Article ID: 2476082.
https://doi.org/10.1155/2019/2476082

[22]   Chen, K., Zhan, M.X., Hu, B.S., Li, Y., He, X., Fu, S.R., et al. (2018) Combination of the Neutrophil to Lymphocyte Ratio and the Platelet to Lymphocyte Ratio as a Useful Predictor for Recurrence Following Radiofrequency Ablation of Hepatocellular Carcinoma. Oncology Letters, 15, 315-323.
https://doi.org/10.3892/ol.2017.7291

[23]   Cruz, J.C., Watchmaker, J.M., Albin, M.M., Wang, L., Wu, G., Baker, J.C., et al. (2019) Neutrophil/Lymphocyte Ratio Predicts Increased Risk of Immediate Progressive Disease following Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology: JVIR, 30, 1887-1892.
https://doi.org/10.1016/j.jvir.2019.08.001

[24]   Chen, Y., Wang, W., Zhang, X., Yu, X., Xi, K., Wen, Y., et al. (2018) Prognostic Significance of Combined Preoperative Platelet-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio in Patients Undergoing Surgery with Stage IB Non-Small-Cell Lung Cancer. Cancer Management and Research, 10, 5411-5422.
https://doi.org/10.2147/CMAR.S177320

[25]   Ocana, A., Nieto-Jiménez, C., Pandiella, A. and Templeton, A.J. (2017) Neutrophils in Cancer: Prognostic Role and Therapeutic Strategies. Molecular Cancer, 16, 137.
https://doi.org/10.1186/s12943-017-0707-7

[26]   Swierczak, A., Mouchemore, K.A., Hamilton, J.A. and Anderson, R.L. (2015) Neutrophils: Important Contributors to Tumor Progression and Metastasis. Cancer and Metastasis Reviews, 34, 735-751.
https://doi.org/10.1007/s10555-015-9594-9

[27]   Dumitru, C.A., Lang, S. and Brandau, S. (2013) Modulation of Neutrophil Granulocytes in the Tumor Microenvironment: Mechanisms and Consequences for Tumor Progression. Seminars in Cancer Biology, 23, 141-148.
https://doi.org/10.1016/j.semcancer.2013.02.005

[28]   Spiegel, A., Brooks, M.W., Houshyar, S., Reinhardt, F., Ardolino, M., Fessler, E., et al. (2016) Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. Cancer Discovery, 6, 630-649.
https://doi.org/10.1158/2159-8290.CD-15-1157

[29]   Zhao, W., Wang, P., Jia, H., Chen, M., Gu, X., Liu, M., et al. (2017) Lymphocyte Count or Percentage: Which Can Better Predict the Prognosis of Advanced Cancer Patients Following Palliative Care? BMC Cancer, 17, 514.
https://doi.org/10.1186/s12885-017-3498-8

[30]   Saleh, R.R., Peinado, P., Fuentes-Antras, J., Perez-Segura, P., Pandiella, A., Amir, E., et al. (2019) Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. Frontiers in Oncology, 9, 1040.
https://doi.org/10.3389/fonc.2019.01040

[31]   Ashokachakkaravarthy, K. and Pottakkat, B. (2020) Mitotic Quiescence in Hepatic Cancer Stem Cells: An Incognito Mode. Oncology Reviews, 14, 452.
https://doi.org/10.4081/oncol.2020.452

[32]   Cho, O., Oh, Y.T., Chun, M., Noh, O.K. and Lee, H.W. (2016) Radiation-Related Lymphopenia as a New Prognostic Factor in Limited-Stage Small Cell Lung Cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 37, 971-978.
https://doi.org/10.1007/s13277-015-3888-y

[33]   Tredan, O., Manuel, M., Clapisson, G., Bachelot, T., Chabaud, S., Bardin-dit-Courageot, C., et al. (2013) Patients with Metastatic Breast Cancer Leading to CD4+ T Cell Lymphopaenia Have Poor Outcome. European Journal of Cancer (Oxford, England: 1990), 49, 1673-1682.
https://doi.org/10.1016/j.ejca.2012.11.028

[34]   Liang, L., Zhu, J., Jia, H., Huang, L., Li, D., Li, Q., et al. (2016) Predictive Value of Pretreatment Lymphocyte Count in Stage II Colorectal Cancer and in High-Risk Patients Treated with Adjuvant Chemotherapy. Oncotarget, 7, 1014-1028.
https://doi.org/10.18632/oncotarget.5835

[35]   Wild, A.T., Ye, X., Ellsworth, S.G., Smith, J.A., Narang, A.K., Garg, T., et al. (2015) The Association between Chemoradiation-Related Lymphopenia and Clinical Outcomes in Patients with Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology, 38, 259-265.
https://doi.org/10.1097/COC.0b013e3182940ff9

[36]   Li, C., Wen, T.-F., Yan, L.-N., Li, B., Yang, J.-Y., Xu, M.-Q., et al. (2013) Scoring Selection Criteria Including Total Tumour Volume and Pretransplant Percentage of Lymphocytes to Predict Recurrence of Hepatocellular Carcinoma after Liver Transplantation. PLoS ONE, 8, e72235.
https://doi.org/10.1371/journal.pone.0072235

[37]   Li, M., Spakowicz, D., Burkart, J., Patel, S., Husain, M., He, K., et al. (2019) Change in Neutrophil to Lymphocyte Ratio during Immunotherapy Treatment Is a Non-Linear Predictor of Patient Outcomes in Advanced Cancers. Journal of Cancer Research and Clinical Oncology, 145, 2541-2546.
https://doi.org/10.1007/s00432-019-02982-4

[38]   Zhang, L.X., Wei, Z.J., Xu, A.M. and Zang, J.H. (2018) Can the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Be Beneficial in Predicting Lymph Node Metastasis and Promising Prognostic Markers of Gastric Cancer Patients? Tumor Maker Retrospective Study. International Journal of Surgery (London, England), 56, 320-327.
https://doi.org/10.1016/j.ijsu.2018.06.037

[39]   Taussig, M.D., Irene Koran, M.E., Mouli, S.K., Ahmad, A., Geevarghese, S., Baker, J.C., et al. (2017) Neutrophil to Lymphocyte Ratio Predicts Disease Progression Following Intra-Arterial Therapy of Hepatocellular Carcinoma. HPB: The Official Journal of the International Hepato Pancreato Biliary Association, 19, 458-464.
https://doi.org/10.1016/j.hpb.2017.01.013

[40]   Ameratunga, M., Chenard-Poirier, M., Moreno Candilejo, I., Pedregal, M., Lui, A., Dolling, D., et al. (2018) Neutrophil-Lymphocyte Ratio Kinetics in Patients with Advanced Solid Tumours on Phase I Trials of PD-1/PD-L1 Inhibitors. European Journal of Cancer (Oxford, England: 1990), 89, 56-63.
https://doi.org/10.1016/j.ejca.2017.11.012

[41]   Lu, S.D., Wang, Y.Y., Peng, N.F., Peng, Y.C., Zhong, J.H., Qin, H.G., et al. (2016) Preoperative Ratio of Neutrophils to Lymphocytes Predicts Postresection Survival in Selected Patients with Early or Intermediate Stage Hepatocellular Carcinoma. Medicine, 95, e2722.
https://doi.org/10.1097/MD.0000000000002722

[42]   Suner, A., Carr, B.I., Akkiz, H., Karakulah, G., Uskudar, O., Yalcin, K., et al. (2019) C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma. Oncology, 96, 25-32.
https://doi.org/10.1159/000492473

[43]   Menter, D.G., Kopetz, S., Hawk, E., Sood, A.K., Loree, J.M., Gresele, P., et al. (2017) Platelet “First Responders” in Wound Response, Cancer, and Metastasis. Cancer and Metastasis Reviews, 36, 199-213.
https://doi.org/10.1007/s10555-017-9682-0

[44]   Menter, D.G., Tucker, S.C., Kopetz, S., Sood, A.K., Crissman, J.D. and Honn, K.V. (2014) Platelets and Cancer: A Casual or Causal Relationship: Revisited. Cancer and Metastasis Reviews, 33, 231-269.
https://doi.org/10.1007/s10555-014-9498-0

[45]   Green, D.L. and Karpatkin, S. (2009) Effect of Cancer on Platelets. Cancer Treatment and Research, 148, 17-30.
https://doi.org/10.1007/978-0-387-79962-9_2

[46]   Wojtukiewicz, M.Z., Sierko, E., Hempel, D., Tucker, S.C. and Honn, K.V. (2017) Platelets and Cancer Angiogenesis Nexus. Cancer and Metastasis Reviews, 36, 249-262.
https://doi.org/10.1007/s10555-017-9673-1

[47]   Xu, X.R., Zhang, D., Oswald, B.E., Carrim, N., Wang, X., Hou, Y., et al. (2016) Platelets Are Versatile Cells: New Discoveries in Hemostasis, Thrombosis, Immune Responses, Tumor Metastasis and Beyond. Critical Reviews in Clinical Laboratory Sciences, 53, 409-430.
https://doi.org/10.1080/10408363.2016.1200008

[48]   Li, B., Zhou, P., Liu, Y., Wei, H., Yang, X., Chen, T., et al. (2018) Platelet-to-Lymphocyte Ratio in Advanced Cancer: Review and Meta-Analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry, 483, 48-56.
https://doi.org/10.1016/j.cca.2018.04.023

[49]   Zheng, J., Cai, J., Li, H., Zeng, K., He, L., Fu, H., et al. (2017) Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: A Meta-Analysis and Systematic Review. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 44, 967-981.
https://doi.org/10.1159/000485396

[50]   Ma, W., Zhang, P., Qi, J., Gu, L., Zang, M., Yao, H., et al. (2016) Prognostic Value of Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma: A Meta-Analysis. Scientific Reports, 6, Article No. 35378.
https://doi.org/10.1038/srep35378

[51]   Shiraki, T., Ishizuka, M., Kubota, K., Kato, M., Matsumoto, T., Mori, S., et al. (2019) An Elevated Neutrophil-to-Lymphocyte Ratio Predicts a Poor Postoperative Survival in Primary Hepatocellular Carcinoma Patients with a Normal Preoperative Serum Level of Alpha-Fetoprotein. Surgery Today, 49, 661-669.
https://doi.org/10.1007/s00595-019-01781-1

 
 
Top